Hereditary Angioedema Research

At HZRM Haemophilie-Zentrum Rhein Main GmbH, much of the clinical trial activity focuses on immune system diseases and hereditary angioedema. These studies are designed to improve both attack treatment and preventive care for people living with this rare swelling disorder.

  • Testing new options for treating acute HAE attacks and easing symptoms faster
  • Evaluating long-term preventive therapies for hereditary angioedema in adolescents, adults, and children
  • Assessing safety, tolerability, and overall effectiveness of emerging angioedema treatments

Research at this site includes both on-demand and prophylactic approaches, with a strong emphasis on making HAE care safer, more reliable, and better suited to different age groups.

Haemophilia A Studies

The site also conducts trials in hemic and lymphatic diseases, especially Haemophilia A and Haemophilia A with inhibitors. These studies aim to support better bleeding prevention and improve treatment outcomes for patients with this inherited bleeding disorder.

  • Studying long-term preventive treatment to reduce bleeding episodes in Haemophilia A
  • Exploring treatment strategies for patients with FVIII inhibitors
  • Evaluating joint health and real-world effectiveness of newer bleeding-prevention therapies

This research helps clarify how newer therapies may improve daily disease control, especially for patients who need ongoing protection against bleeds.

Pediatric and Family-Focused Rare Disease Trials

The Hamophilie Zentrum Rhein Main participates in studies that include children, adolescents, and infants, reflecting a broader focus on congenital and hereditary diseases. These trials are important for understanding how rare disease treatments perform across different age groups.

  • Assessing safety and treatment response in pediatric hereditary angioedema
  • Investigating preventive therapy options for young children with HAE
  • Studying early-life treatment approaches in Haemophilia A, including patients with and without inhibitors

By including younger patients, the research supports more age-appropriate care and helps expand treatment choices for rare inherited conditions.